Summary
11.57
0.89
(8.29%)
08/13/2026
Candel Therapeutics, Inc. (CADL)Key Facts
Performance
Historical returns1D
8.29%
1W
0.95%
1M
10.79%
3M
22.48%
6M
90.71%
1Y
68.19%
5Y
29.30%
Snapshot
Key statisticsClose
11.57
Change
0.89
Change %
8.29%
Open
10.78
Day Range
10.48 – 11.57
Volume
1,444,774
Avg Vol (20d)
1,107,506
Rel Vol
1.30x
52W Range
4.35 - 11.36
vs 52W High
1.85%
vs 52W Low
165.86%
Gap
0.02
Market Cap
USD 274.78M
Beta
-0.93
Price Chart
Advanced chartCompareLast 730 data points are shown. To view all data, Upgrade to PRO plan!
New Highs
Historical highs| Period | New Highs | From Last |
|---|---|---|
| 5-Day | 3× | 0.00% |
| 1-Month | 8× | 0.00% |
| 3-Month | 10× | 0.00% |
| 6-Month | 22× | 0.00% |
| YTD | 25× | 0.00% |
| Period | New Highs | From Last |
|---|---|---|
| 52-Week | 19× | 0.00% |
| 2-Year | 13× | -5.28% |
| 3-Year | 20× | -17.39% |
| 5-Year | 7× | -17.39% |
| 10-Year | n/a | n/a |
Financial SnapshotFY 2025
Full financialsRevenue
n/a
Net Income
-USD 38.18M
-30.8% YoY
EPS
-0.72
-58.6% YoY
Gross Margin
n/a
Operating Margin
n/a
Net Margin
n/a
EBITDA
-USD 35.22M
Free Cash Flow
-USD 38.90M
ROE
-73.5%
ROA
-30.5%
Debt / Equity
0.04x
net debt -USD 117.83M
Cash & Equiv.
USD 119.73M
Fundamental Ratings
MainC+
RecommendedSell
DCFNeutral
ROEStrong Sell
ROAStrong Sell
Debt/EquityBuy
P/EStrong Sell
P/BNeutral
Latest Earnings
- CADL reported last earnings on 2026-05-14.
- EPS of $-0.14 vs $-0.22 estimated — surprise $0.08.
- Revenue of $0M vs $0M estimated — surprise $0M.
News
All newsCandel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
NEEDHAM, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced financial results for the...
Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up
Candel Therapeutics NASDAQ: CADL is advancing two off-the-shelf viral immunotherapy candidates designed for local administration intended to generate systemic immune responses against tumors, Chief Scientific Officer Francesca Barone said at the Canaccord Genuity Growth Conference in Boston.
Candel Therapeutics: Getting Closer, And Building Out More Paths
Candel Therapeutics, Inc. remains a Buy as its lead asset, CAN-2409, advances toward FDA submission in prostate cancer with strong phase 3 data. CADL is well-capitalized, holding $194.8M in cash, providing runway into Q1 2028 and supporting pivotal trials in prostate and lung cancer. CAN-2409's...
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on July 31,...
Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that an abstract was...
Candel Therapeutics to Present at Canaccord Genuity's 46th Annual Growth Conference in Boston
NEEDHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that the Company will...
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEEDHAM, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on July 6, 2026,...
Candel Therapeutics: An Overlooked Late-Stage Biotech With Real Potential
Candel Therapeutics is transitioning from a high-risk clinical-stage biotech to a late-stage oncology company with a BLA-directed lead asset. CAN-2409 has achieved positive Phase III results in localized prostate cancer, with additional promising data in NSCLC and PDAC, supporting a 'pipeline in a...
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
Phase 3 clinical trial will evaluate aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab versus standard-of-care docetaxel chemotherapy in patients with metastatic, non-squamous, non-small cell lung cancer (NSCLC) with progressive disease despite prior...
Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer
NEEDHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the appointment of...
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
NEEDHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the publication of...
Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data
Candel Therapeutics NASDAQ: CADL Chief Executive Officer Dr. Paul Peter Tak said the company remains focused on advancing its viral immunotherapy programs following newly presented prostate cancer data and as it prepares for a planned biologics license application submission by the end of the year.
Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade
The mean of analysts' price targets for Candel Therapeutics (CADL) points to a 148.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Candel Therapeutics, Inc. (CADL) Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagene besadenovec in Localized Prostate Cancer Transcript
Candel Therapeutics, Inc. (CADL) Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagene besadenovec in Localized Prostate Cancer Transcript
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
NEEDHAM, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced new results from...
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
NEEDHAM, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced financial results for the...